HUP0301103A2 - Cardialis inzulinrezisztenciával kapcsolatos állapotok kezelése és megelőzése - Google Patents

Cardialis inzulinrezisztenciával kapcsolatos állapotok kezelése és megelőzése

Info

Publication number
HUP0301103A2
HUP0301103A2 HU0301103A HUP0301103A HUP0301103A2 HU P0301103 A2 HUP0301103 A2 HU P0301103A2 HU 0301103 A HU0301103 A HU 0301103A HU P0301103 A HUP0301103 A HU P0301103A HU P0301103 A2 HUP0301103 A2 HU P0301103A2
Authority
HU
Hungary
Prior art keywords
insulin resistance
prevention
treatment
associated conditions
resistance associated
Prior art date
Application number
HU0301103A
Other languages
English (en)
Inventor
Ameet Nathwani
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of HUP0301103A2 publication Critical patent/HUP0301103A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány emberekben vagy más emlősökben előforduló cardialisinzulinrezisztencia vagy cardialis inzulinrezisztenciával kapcsolatosállapotok kezelésére vagy megelőzésére szolgáló eljárásra vonatkozik,amelynek során egy PPARy agonistának, például az 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}-benzil]-2,4-dioxo-tiazolidinnek[(I)vegyületnek] vagy egy gyógyászatilag elfogadható származékánakhatásos, nem toxikus és gyógyászatilag elfogadható mennyiségét adjákbe a betegnek. Ó
HU0301103A 2000-06-16 2000-06-16 Cardialis inzulinrezisztenciával kapcsolatos állapotok kezelése és megelőzése HUP0301103A2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/002347 WO2001095906A1 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions

Publications (1)

Publication Number Publication Date
HUP0301103A2 true HUP0301103A2 (hu) 2003-08-28

Family

ID=9884792

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301103A HUP0301103A2 (hu) 2000-06-16 2000-06-16 Cardialis inzulinrezisztenciával kapcsolatos állapotok kezelése és megelőzése

Country Status (15)

Country Link
EP (1) EP1292301A1 (hu)
JP (1) JP2004503499A (hu)
CN (1) CN1592620A (hu)
AP (1) AP2002002688A0 (hu)
BG (1) BG107384A (hu)
BR (1) BR0017254A (hu)
CA (1) CA2436116A1 (hu)
DZ (1) DZ3389A1 (hu)
EA (1) EA200300028A1 (hu)
HU (1) HUP0301103A2 (hu)
IL (1) IL153452A0 (hu)
MX (1) MXPA02012619A (hu)
NO (1) NO20026000L (hu)
WO (1) WO2001095906A1 (hu)
YU (1) YU1203A (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation

Also Published As

Publication number Publication date
AP2002002688A0 (en) 2002-12-31
EP1292301A1 (en) 2003-03-19
EA200300028A1 (ru) 2003-04-24
WO2001095906A1 (en) 2001-12-20
NO20026000D0 (no) 2002-12-13
NO20026000L (no) 2003-02-11
CN1592620A (zh) 2005-03-09
BR0017254A (pt) 2004-01-06
CA2436116A1 (en) 2001-12-20
JP2004503499A (ja) 2004-02-05
YU1203A (sh) 2006-05-25
IL153452A0 (en) 2003-07-06
MXPA02012619A (es) 2003-04-10
BG107384A (bg) 2003-09-30
DZ3389A1 (fr) 2001-12-20

Similar Documents

Publication Publication Date Title
AU4319699A (en) Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof
SG149814A1 (en) Compositions and methods for treating diabetes
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
WO2007130075A8 (en) Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
TW200505900A (en) Muscarinic agonists
NO20055892L (no) Karboksylsyrederivater
EP1593379A3 (en) Uses of PPAR-gamma agonists in neutrophil-induced diseases
HUP0300725A2 (hu) Az inzulinrezisztencia-szindróma kezelése CGMP PDE5 inhibitorokkal
HUP0104108A2 (hu) Eljárás diabétesz kezelésére egy aP2 inhibitor vagy kombinációja alkalmazásával
NO20100093L (no) Peptidomimetiske protease-inhibitorer
TW200420549A (en) Thiazole derivatives
WO2007075695A3 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2003028715A3 (en) Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis
DK1154795T3 (da) Middel til behandling af diagnosticering af restless legs syndrom
WO2001041754A8 (en) Inhibitors of collagen-induced platelet aggregation
WO2002056745A3 (en) Method of treating parkinson's disease
HUP0003260A2 (hu) Gyógyszerkészítmény diabetes kezelésére rosziglitazonnal és inzulinnal
SE0004101D0 (sv) New use
PL372661A1 (en) Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections
WO2000066098A3 (en) Vitamin d derivatives for the treatment of systemic lupus erythematosus
HUP0301103A2 (hu) Cardialis inzulinrezisztenciával kapcsolatos állapotok kezelése és megelőzése
WO2001070233A3 (en) Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
ATE214926T1 (de) Verwendung von (r-(z))-alpha-(methoxyimino)-alpha-(1-azabicycl (2.2.2.) oct-3-yl) acetonitril zur hemmung der amyloid-beta-a4-bildung bei der alzheimerschen krankheit
WO2002053099A3 (en) Methods and compositions for treating periodontal disease
NO20032006D0 (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser